FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice.
about
Clinical applications, limitations and future role of transient elastography in the management of liver disease.Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and BClinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis CTransient Elastography and Controlled Attenuation Parameter for Diagnosing Liver Fibrosis and Steatosis in Ontario: An Economic Analysis.Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C.Association of adiponectin gene polymorphism with nonalcoholic fatty liver disease in Taiwanese patients with type 2 diabetes.Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing CholangitisThe Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease.Serial Liver Stiffness Measurements and Monitoring of Liver-Transplanted Patients in a Real-Life Clinical Practice.Liver Fibrosis: Causes and Methods of Assessment, A Review.Targeting Hepatic Fibrosis in Autoimmune Hepatitis.Direct-Acting Antiviral Therapy for Chronic HCV Infection Results in Liver Stiffness Regression Over 12 Months Post-treatment.Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders.Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients.ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.Assessment of hepatic fibrosis with superb microvascular imaging in hepatitis C virus-associated chronic liver diseases.Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.Serum fibrosis biomarkers predict death and graft loss in liver transplantation recipients.Low-fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States.Myths and mysteries about staging hepatic fibrosis by fibroscan.The aspartate aminotransferase-to-platelet ratio and the evaluation of non-alcoholic fatty liver disease.Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease.Arterial hypertension as an uninvited player in hepatic stiffness?Nonalcoholic fatty liver with a hepatic arterial buffer response strongly associated with future metabolic disease.The role of noninvasive tests and liver biopsy in the diagnosis of nonalcoholic fatty liver diseasePrevalence and Determinants of Significant Liver Fibrosis by Vibration-Controlled Transient Elastography in Thai Chronic Hepatitis B PatientsLiver function tests in identifying patients with liver disease
P2860
Q26768262-5DB5C7FF-6FF6-47FB-90FB-1571C5056334Q26777916-8D697B1D-1707-4A15-A733-97E7497B845CQ28080225-036C8A29-401C-458F-A1BC-77A77D271D8DQ28084154-A99078E5-4958-4ED0-99FF-FBCD43A6C4EAQ30397191-57FE0F45-3F2C-4064-B8CE-D1349096FD6BQ33435950-66661E08-C29A-42CD-B880-A752C1C633B3Q33655116-DD6862D0-3A18-416D-AB7C-C7232BD4111BQ35652518-4CEF1928-BCAA-41C1-B01E-268202C07EEEQ35932326-3FBF5214-905C-4D78-BB9E-44FF41E0310DQ36752084-B301530B-4308-497C-BF61-5A0F16383039Q36880302-7F872CDD-D53B-44A3-AE7F-1F03367668E3Q37587196-8BC2391E-16AB-4C62-8BB6-BE364E5C71F2Q38759277-C05931A2-0D2C-46DF-9C66-5D5B4779A7A0Q38902371-782F65DA-98BE-4867-9B24-A37E88DB76E3Q40049943-608B9753-B75C-4DBB-AC73-C3CCDF3E1D94Q40306589-D3FAA817-4F45-4EEB-A42C-C2CC6218DFFEQ40330653-451FF330-D2C5-469D-86D4-E2D2B88542FCQ40416496-27ECF45C-FE2E-41A1-9FBC-F5EA00E6AE80Q40643820-56662342-AD67-4D4B-BDC1-E6A32B449266Q41456415-EBB0F26E-20C0-4974-92FE-775A55FA16ECQ41565564-5D759D2F-BDDF-471E-96C7-24A39142CFE6Q42145719-3CD1EBE3-004B-4D53-8989-9D9DB59CDB01Q42736140-1408BF1D-4C01-4A2C-A2C9-40DD6D5709EAQ42974082-EC431FA4-DC04-4133-AEE3-D7D2D70B6F8EQ45024243-3A77E30A-DE66-42C4-946F-D86C961C1057Q45066338-F28D6C72-D36F-47B3-B75E-2C9EFB1EDDB5Q53000723-6B87AC13-052E-416C-9682-4D83E74C6597Q55361713-F5EB1659-86FA-4879-8798-7F2B433BDD99Q58570758-275F918C-F35C-4381-81BD-F16183A2A93AQ58587227-C959FA9F-8784-4E6E-A834-E1CC00CC096CQ58712977-1033FA41-3CBA-404B-87CB-6A0D31BE20A7
P2860
FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
FibroScan (vibration-controlle ...... in the United States practice.
@en
type
label
FibroScan (vibration-controlle ...... in the United States practice.
@en
prefLabel
FibroScan (vibration-controlle ...... in the United States practice.
@en
P1476
FibroScan (vibration-controlle ...... in the United States practice.
@en
P2093
Elliot B Tapper
P356
10.1016/J.CGH.2014.04.039
P407
P577
2014-06-05T00:00:00Z